Please use this identifier to cite or link to this item: https://doi.org/10.3390/vaccines9121466
Title: Equity in vaccine trials for higher weight people? A rapid review of weight-related inclusion and exclusion criteria for COVID-19 clinical trials
Authors: Campbell, Jessica
Sutherland, Juliet
Bucknall, Danielle
O’hara, Lily
Heywood, Anita
Hobbs, Matthew
Ballantyne, Angela 
Gray, Lesley
Keywords: BMI
Clinical trial
COVID-19
Equity
Higher weight
Inequity
Vaccination
Vaccine
Issue Date: 11-Dec-2021
Publisher: MDPI
Citation: Campbell, Jessica, Sutherland, Juliet, Bucknall, Danielle, O’hara, Lily, Heywood, Anita, Hobbs, Matthew, Ballantyne, Angela, Gray, Lesley (2021-12-11). Equity in vaccine trials for higher weight people? A rapid review of weight-related inclusion and exclusion criteria for COVID-19 clinical trials. Vaccines 9 (12) : 1466. ScholarBank@NUS Repository. https://doi.org/10.3390/vaccines9121466
Rights: Attribution 4.0 International
Abstract: Higher weight status, defined as body mass index (BMI) ? 30 kg/m2, is frequently described as a risk factor for severity and susceptibility to severe acute respiratory syndrome coron-avirus 2 (SARS-CoV-2) disease (known as COVID-19). Therefore, study groups in COVID-19 vaccine trials should be representative of the weight spectrum across the global population. Appropriate subgroup analysis should be conducted to ensure equitable vaccine outcomes for higher weight people. In this study, inclusion and exclusion criteria of registered clinical trial protocols were reviewed to determine the proportion of trials including higher weight people, and the proportion of trials conducting subgroup analyses of efficacy by BMI. Eligibility criteria of 249 trial protocols (phase I, II, III and IV) were analysed; 51 protocols (20.5%) specified inclusion of BMI > 30, 73 (29.3%) specified exclusion of BMI > 30, and 125 (50.2%) did not specify whether BMI was an inclusion or exclusion criterion, or if BMI was included in any ‘health’ screenings or physical examinations during recruitment. Of the 58 protocols for trials in phase III and IV, only 2 (3.4%) indicated an intention to report subgroup analysis of vaccine efficacy by weight status. Higher weight people appear to be significantly under-represented in the majority of vaccine trials. This may result in reduced efficacy and acceptance of COVID-19 vaccines for higher weight people and exacerbation of health inequities within this population group. Explicit inclusion of higher weight people in COVID-19 vaccine trials is required to reduce health inequities. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Source Title: Vaccines
URI: https://scholarbank.nus.edu.sg/handle/10635/233003
ISSN: 2076-393X
DOI: 10.3390/vaccines9121466
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_vaccines9121466.pdf587.19 kBAdobe PDF

OPEN

NoneView/Download

Page view(s)

13
checked on Dec 1, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons